DTE vs PMCB
DTE (DTE) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
DTE (DTE) common stock.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
DTE does not have a complete income-statement cache yet.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
DTE currently screens at market cap $0. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the DTE and PMCB stock pages for the full models.
Not investment advice.